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Introduction: Chronic graft-versus-host disease (cGVHD) is the
major long term complication of allogeneic stem cell transplantation
and shares similarities with auto-immune diseases, like systemic scle-
rosis. Although the contribution of donorT-cells in the development
of both acute and chronicGVHD is beyond doubt; the role of B-cells
is less defined. Two observations suggest that B-cells do contribute
to cGVHD; autoantibodies can be detected in 15-90% of patients
and several small-scale retrospective clinical studies demonstrated
that in vivo depletion of B-cells with the CD20-specific Ab rituximab
results in amelioration of cGVHD symptoms in heavily pretreated
steroid-refractory patients.
Objective: In order to prospectively investigate B-cell depletion as
therapy for cGVHD, we have studied the efficacy of the rituximab
in patients with steroid-refractory extensive cGVHD.
Methods: In an ongoing prospective phase I/II study 15 patients
were treated with rituximab (375 mg/m2 per week for 4 consecutive
weeks). Clinical responses were monitored monthly for 1 year ac-
cording to the NIH criteria.
Results: A total of 60 infusions were administered to 15 patients.
The clinical responses were so far analyzed in 12 patients. Median
follow-up 6.5 months (range 1-13). Eight patients showed a partial
response (67%) of which 42% had an ongoing response up to 1
year of follow-up and 25% relapsed. Two relapsed patients were
retreated 8 months after cessation of the initial treatment and
showed again a partial response. In patients with deep sclerosis
(n5 10), sclerotic features disappeared completely or partially in
80%. In patients with involvement of eyes (n5 10), mucosa
(n5 4) and gastro-intestinal tract (n5 4) response was observed
in 50%, 25% and 25%. Consequently, prednisone dosage could
be reduced in 58% and in 33% of the patients prednisone treat-
ment was stopped.
Conclusion: Rituximab treatment is a feasible and effective treat-
ment in patients with steroid refractory cGVHD. In addition, also
patients with relapse of cGVHD after cessation of rituximab treat-
ment can be successfully treated. Thereby, sclerotic lesions of the
skin improved in the majority of patients whereas eye, mucosal and
gastro-intestinal tract involvement was less reversible. We speculate
that the lack of improvement of eye and mucosal involvement is
a consequence of an early and irreversible destruction of lacrimal
and salivary glands and this argues for an upfront application of
rituximab in cGVHD.401
ORAL HUMAN RECOMBINANT LACTOFERRIN PREVENTS ACUTE GRAFT-
VERSUS-HOST DISEASE AND STIMULATES RECONSTITUTION OF DONOR
BONE MARROW-DERIVED T-CELLS IN A MOUSE MODEL OF BONE MAR-
ROW TRANSPLANTATION
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Background: Lactoferrin, an iron-binding protein with multiple
physiological functions (anti-microbial, anti-inflammatory, and im-
munomodulatory), is a component of mammalian milk. Lactoferrin
has immune modulatory effects through interaction with natural
killer cells, T-cells and interfering with cytokine production. There
is in vitro evidence that lactoferrin can reduce lipopolysaccaride-in-
duced release or pro-inflammatory cytokines in mice and human
possibly through scavenging lipopolysaccaride (LPS) in the intesti-
nal lumen. The central hypothesis of this research project was that
administration of human recombinant lactoferrin (hrLF) tomice un-
dergoing allogeneic bone marrow transplantation (allo BMT) will
reduce the pro-inflammatory effects of the conditioning regimens,
and gut epithelial tissue damage, resulting in less non-specific activa-
tion of donor T-cells that cause GvHD.Methods: Irradiated (11 Gy) C57BL/6 recipient received 5106 T
cell depleted (TCD) bone marrow cells and 3106 plastic non-ad-
herent splenocytes from naı¨ve BA.B10 congenic donors. To test the
hypothesis we studied the effect of oral hrLF administration on
GvHD in murine models of allo BMT. Lactoferrin (hrLF)
(75 mg/mouse) or PBS was administered by gastric gavage from
day -4 for up to 30 days in surviving recipients. GvHD was mon-
itored clinically by using criteria such as weight reduction and di-
arrhea. Survival was assessed. Flow cytometry was used to
determine donor chimerism, immune reconstitution and the fre-
quency of naive CD62L+ T cells.
Results: Oral hrLF reduced acute GvHD and the experimental
group survived 100%; however, 67% of the control group survived.
There was a significant difference in the number of peripheral blood
nucleated cells (PBNC) and bone marrow nucleated cells (BMNC)
between the experimental and control groups (p5 0.02 and
p5 0.01). No significant difference in bone marrow CD4+ and
CD8+ T-cells, andCD4+CD62L+T-cells from donor spleen derived
cells between two groups was found.
Conclusion: Oral hrLF treatment successfully controlled GvHD
and suppressed donor T-cells. There were significant differences
between lactoferrin group and the control mice including diar-
rhea, weight loss, and numbers of nucleated cells. Hence, prophy-
lactic use of lactoferrin is a novel therapeutic approach for
prophylaxis of GvHD in patients undergoing allogeneic
HSCT.402
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Therapies for localized prostate cancer include curative surgery
and radiotherapy while treatment for metastatic disease is palliative
and based on depriving the tumor cells of their androgen stimulation
that reduces tumor growth rate. Therefore, we started to investigate
the potential of allogeneic SCT as a treatment for non-curable pros-
tate cancer.
Two patients underwent allogeneic SCT with PBSC from HLA-
identical sisters after a non-myeloablative conditioning regimen as
treatment for metastatic prostate adenocarcinoma. Frequencies of
prostate-specific T cells in the peripheral blood of the patients, sib-
ling donors and a group of control individuals were determined by
flow cytometry using tetrameric and pentameric HLA A2 com-
plexes containing peptides derived from the prostate specific anti-
gen (PSA). Cytotoxic activity of PSA-peptide-specific T-cells
against peptide-pulsed target cells was analyzed ex vivo by 51Cr-re-
lease assays.
Stable clinical and laboratory remission lasting for more than 4
years was observed after SCT for the first transplanted patient.
The patient is now 6.5 years after SCT but now slowly increasing
in PSA indiacting tumor progression. The PSA level is today 12
ng/mL. The second patient has decreased in PSA from 257 ng/mL
before SCT to 70 ng/mL and without clinical signs of progression
one year after SCT. Both patients are doing clinically excellent
and have a good quality of life. In the second patient a dramatic in-
crease was detected in PSA levels during development of GVHD.
After treatment of GVHD the PSA levels decreased continuously.
We believe that the sudden increase of PSA was due to an antitumor
attack of prostate-specific T cells indicating a graft-versus-tumor ef-
fect. Using HLA containing pentamers with PSA-derived peptides
we could detect prostate-specific CD8+ T cells in both patients in
high frequencies over several months. Furthermore, higher frequen-
cies of PSA-specific T-cells were revealed in the peripheral blood of
the patients and female controls as compared with male healthy
controls.
Our data suggest that allogeneic SCT led to the generation of a T
cell mediated prostate-specific immunity in both patients. The in vi-
tro and ex vivo immunological monitoring performed indicate an
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ents a novel treatment approach involving allogeneic SCT in pros-
tate cancer patients who do not respond to chemotherapy and/or
cannot undergo prostectomy.403
PERIPHERAL BLOOD STEM CELLS AND GRANULOCYTE COLONY-STIMU-
LATING FACTOR ARE ASSOCIATED WITH ACUTE GRAFT-VERSUS-HOST
DISEASE
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Does granulocyte colony-stimulating factor (G-CSF) increases
GVHD or not? A mouse model of GVHD showed that G-CSF in-
duce GVHD after bone marrow (BM) transplantation (Morris et al,
Nature Med 15:436, 2009). Total body irradiation (TBI) increased
G-CSF receptors on host dendritic cells, stimulating acute GVHD.
Their report prompted us to reassess the role of G-CSF prophy-
laxis in our HSCT patients. During 1994–2002, 260 patients
were given G-CSF prophylaxis. Patients not given G-CSF
(n5 205) who underwent HSCT from 1993 to 2003 were controls.
We included all patients receiving BM (n5 286) or peripheral
blood stem cell (PBSC) grafts (n5 179) from HLA-identical sib-
lings (n5 225) or HLA-A, -B, or DRß1 genomically identical un-
related donors (MUDs; n5 240). The G-CSF group had more
MUD transplants, fewer patients receiving reduced-intensity con-
ditioning (RIC), more patients receiving antithymocyte globulin
(p\0.001), and AB0 mismatch was commoner (p5 0.03). Patients
treated with G-CSF had acute GVHD (grades II–IV) of 29%, vs.
19% in the controls (p\0.01). GVHD occurred in 33% of pa-
tients given PBSC, as compared to 19% of those given BM
(p\0.001). There was no significant difference in incidence of
GVHD between HLA-identical sibling transplants and MUD
transplants, between those with myeloablative conditioning and
those with RIC, or between those treated with TBI and chemother-
apy and those treated with chemotherapy only. In patients condi-
tioned with chemotherapy, 34% in the G-CSF group developed
acute GVHD as compared to 21% in the controls (p5 0.035). In
patients treated with TBI, those given G-CSF had an incidence
of acute GVHD (grades II–IV) of 26% as opposed to 17% in the
controls (p5 0.10). In PBSC recipients, 39% in the G-CSF group
developed acute GVHD as compared to 24% in the controls
(p5 0.025). In recipients of BM, the corresponding figures were
22% and 15%, respectively, in the two groups (p5 0.19). In the
present study, a multivariate analysis showed that acute GVHD
of grades II–IV was associated with PBSC grafting (hazards ratio
(HR)5 2.29, p\0.0001), female donors (HR5 1.74, p5 0.005),
major AB0 mismatch (HR5 1.58, p5 0.03), and
G-CSF (HR5 1.52, p5 0.03). Differences were adjusted. There
were no differences between the two groups regarding non-relapse
mortality, relapse, and survival.
Conclusion: G-CSF induces GVHD in mice, but differs compared
to humans regarding the role of source of stem cell and conditioning
regimen.404
SIROLIMUS, TACROLIMUS, AND RABBIT ATG (RATG) AS GRAFT-VERSUS-
HOST PROPHYLAXIS IN PATIENTS UNDERGOING UNRELATED DONOR
HEMATOPOIETIC STEM CELL TRANSPLANT (HCT)
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The use of sirolimus combined with tacrolimus +/- low-dose
methotrexate (MTX) recently showed a promising result in pre-
venting acute GVHD after unrelated donor HCT (Antin et al.
Blood 2003) although a significant number of patients still experi-
enced chronic GVHD. In an attempt to further improve the out-
come, we have developed a novel combination of tacrolimus (FK),
sirolimus (SIR) and r-ATG +/- MTX (MTX given for patients
with a mismatch donor) and studied in a total of 51 patients
who underwent unrelated donor HCT from 7/5/2006 to 7/31/2009. The median age at transplant was 56 (range: 16 -71).
Twenty were female and 31 were male. Indications for transplant
were as follows: ALL (n5 12, CR1/25 11, Induction Failure5 1),
AML (n5 19: CR1/25 12: relapse/induction failure5 7), CML
(n5 4: CP1/25 2, AP/BC5 2), non-Hodgkin Lymphoma
(n5 5); CLL (n5 1), MDS (n5 8), MPD (n5 2). Thirty one pa-
tients received reduced-intensity conditioning (fludarbine/melpha-
lan [Flu/Mel]) and 20 received full-intensity conditioning (FTBI/
VP-16: n5 13, FTBI/Cytoxan: n5 7). All received PBSC graft ex-
cept for two patients who received bone marrow graft. Twenty-
nine of 51 patients had a 10/10-match donor by high resolution
HLA typing. Engraftment rate was 92.2% (n5 47) with the me-
dian neutrophil engaftment at 15 days (range: 10-39). Eighteen
patients (38% of 47 engrafted) developed grade II-IV acute
GVHD (grade III5 3, grade IV5 0). Chronic GVHD developed
in 21 of 37 evaluable patients (57%, limited n5 7, extensive
n5 14). We observed TTP/HUS in 10 patients (20%) and one
case of VOD. Eighteen (42%) of 43 patients at risk (R+ or D+)
developed CMV reactivation, while 10 patients developed EBV re-
activation (19.6%). After a median follow up of 11 months (range:
2-35) 38 patients were alive. The 1-year probabilities of overall
survival, disease-free survival (DFS), and relapse rate were 74.7%
(63-83%), 73.2% (62-82%), and 11% (5-25%), respectively.
Non-relapse mortality was 14.7% (8-26%) at 100 day and
17.5% (10-29%) at 1 year. There were no significant differences
in the outcomes according to conditioning regimens, although
there was a trend for lower NRM with Flu/Mel (11% vs. 27%
at 1 year, p5 0.1).
In summary FK/SIR combined with r-ATG +/- MTX is associ-
ated with a promising early result in GVHD prevention and survival
in this high-risk population. However, the rate of graft failure (n5 4)
appeared greater than our historic data, which is being further inves-
tigated at our institution.405
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In a previously reported multicenter randomized standard-ther-
apy controlled trial, a 12-week course of ECP resulted in several
beneficial outcomes in patients (pts) with steroid-refractory/intol-
erant/dependent cGVHD. (Flowers et al, Blood 112:2667-74.
2008). We conducted an open-label cross-over extension study
to provide access to ECP for participants in the standard of care
arm of this randomized study and enrolled 29 pts. ECP was ad-
ministered 3 times during week 1, 2 treatments weekly until
week 12 then 2 treatments until week 24. The median age of the
study cohort was 43 (20-67) years and 26 pts (90%) had extensive
cGVHD. Onset was de novo in 11 (37.9%), progressive in 15
(51.7%) and quiescent in 3 (10.3%). Twenty-five of 29 pts
(86%) completed the 24 week course of ECP open-label treat-
ment. Causes for not completing the 24-weeks were GVHD pro-
gression (n5 2), 1 suicide, and 1 withdrawal of consent. Mean
daily steroid dose was 18.4 mg at the first ECP visit in this exten-
sion study (baseline). The median total skin score (TSS) was 7.8
(1.0-18.5) at the start of this cross-over extension study. The me-
dian percent change in TSS from baseline to week 12 and week 24
was -8.0 and -22.7, respectively. Four pts (14%) and 7 pts (24%)
achieved a $50% reduction in steroid dose at weeks 12 and 24, re-
spectively. In 4 pts (14%) and 8 pts (28%) a $50% reduction in
steroid dose and a final steroid dose of\10 mg/day at weeks 12
and 24 was obtained respectively. Complete or partial skin
response at week 24 was observed in 4 pts (14%) by investigator
assessment.
